Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Nov 19;9(2):45–52. doi: 10.5301/heartint.5000216

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014, Wichtig Publishing

© 2014 The Authors. This article is published by Wichtig Publishing and licensed under Creative Commons Attribution-NC-ND 4.0 International CC BY-NC-ND 4.0). Any commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.wichtig.com

PMC Copyright notice

Fig. 1 - — The influence of statin therapy on plasma-oxidized low-density lipoprotein (OxLDL) biomarkers and high-sensitivity C-reactive protein (CRP). apoB-IC = apolipoprotein B-100 immune complexes; CI = confidence interval; IC/apoB = immune complexes per apolipoprotein B-100; Ig = immunoglobin; Lp(a) = lipoprotein (a); MDA = malondialdehyde; MDA/apoB = malondialdehyde epitopes per apolipoprotein B-100; OxPL/apoB = oxidized phospholipid epitopes per apolipoprotein B-100. From The New England Journal of Medicine, Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Vol. 345, No. 23, pp. 1667-1675. Copyright © 2001 Massachusetts Medical Society (83). Adapted with permission from Massachusetts Medical Society. See text for details.